ClinicalTrials.gg
CompletedNCT04864834MylightUpdated Mar 26, 2024Results posted

Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration

A Phase 3 interventional study of SOK583A1 (40 mg/mL) and Eylea EU (40 mg/mL) in Neovascular Age-related Macular Degeneration, sponsored by Sandoz. Completed at 102 sites in 16 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-03-26.

Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
485
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
7th of 66
485 · median 55
Started
2021
with 1 other
Phase 3
18 of 66
1 open now
Registered
48th of 66
by date
Lead sponsor
3 of 66
Sandoz

Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 7th largest by enrollment, is one of 2 that started in 2021, is one of 18 in phase 3, and was the 48th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

Purpose and rationale: To demonstrate similar efficacy, safety and immunogenicity of SOK583A1 and Eylea EU as per Eylea approved treatment regimen in patients with nAMD.

The primary clinical question of interest is: Does SOK583A1 have similar efficacy as Eylea EU in terms of mean change in BCVA score in participants with nAMD who are anti-VEGF naive, without important protocol deviations and adherent to the treatment and completed the treatment to Week 8?

Read the detailed description

BCVA: Best-Corrected Visual Acuity Eylea EU: Europe-authorized Eylea® nAMD: Neovascular Age-related Macular Degeneration VEGF: Vascular Endothelium Growth Factor

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participants eligible for inclusion in this study must meet all of the following criteria:

  1. Signed must be obtained prior to participation in the study
  2. Participants must be 50 years of age or older at Screening
  3. Anti-VEGF treatment-naive patients for either eye and systemically
  4. Study eye diagnosed with active CNV lesions (type 1 and/ or type 2) secondary to AMD and/or Retinal Angiomatous Proliferation lesions (type 3), affecting the central subfield. Active CNV lesion is defined by the presence of leakage as evidenced by fluorescein angiography, and intra- or subretinal fluid as evidenced by optical coherence tomography, both confirmed by the CRC at Screening
  5. Total area of CNV (including both classic and occult components) must comprise > 50% of the total lesion area in the study eye, confirmed by the CRC at Screening
  6. BCVA between 73 and 38 letters, both inclusive, in the study eye at Screening and Baseline using ETDRS testing charts
  7. Willing and able to comply with all study procedures, and be likely to complete the study
  8. Clear ocular media and adequate pupil dilatation in both eyes to permit good quality photographic imaging.

Participants meeting any of the following criteria are not eligible for inclusion in this study.

Ocular conditions and treatments:

  1. Previous treatment with any anti-VEGF therapy in either eye or drugs in study eye or fellow eye, at any time prior to Baseline
  2. Participant has received any approved treatment for nAMD (other than vitamin and dietary supplements) in the study eye and at any time prior to Baseline
  3. Presence of other causes of CNV, including pathologic myopia (spherical equivalent of -8 diopters or more negative), ocular histoplasmosis syndrome, angioid streaks,choroidal rupture, or multifocal choroiditis in the study eye, assessed by imaging at screening by CRC and appropriately stated in the multi-modal eligibility confirmation report
  4. Any active or suspected intraocular or periocular infection or suspected active intraocular inflammation (e.g infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis) in either eye at Screening or Baseline
  5. Subfoveal fibrosis, atrophy, or scarring extending > 50% of total lesion area in the study eye as assessed by the Investigator at Screening and confirmed by the CRC prior to randomization
  6. Subretinal hemorrhage that is ≥ 50% of the total lesion area in the study eye, or if the subretinal hemorrhage involving the fovea is 1 or more disc areas (≥ 2.54 mm2 ) in size in the study eye, as assessed by Fluorescein Angiography (FA) and confirmed by the CRC
  7. Retinal pigment epithelium (RPE) rip/tear in the study eye at Screening or Baseline
  8. Current vitreous hemorrhage or history of vitreous hemorrhage in the study eye within 4 weeks prior to Baseline
  9. History or evidence of the following, in the study eye:

    • Intraocular (including cataract surgery) or refractive surgery within the 90 day period prior to Baseline. The yttrium aluminum garnet (YAG) posterior capsulotomy is allowed no later than 4 weeks prior to Baseline
    • Previous penetrating keratoplasty or vitrectomy
    • Previous panretinal photocoagulation
    • Previous photodynamic therapy
    • Previous submacular surgery or other surgical intervention for AMD
    • Retinal detachment or treatment or surgery for retinal detachment
    • Any history of macular hole of stage 2 and above
    • Prior trabeculectomy or other filtration surgery
    • Ocular trauma within the 6-months period prior to Baseline
  10. History of to any of the study treatments or its , or sensitivity to fluorescein dye, as assessed by the Investigators
  11. Uncontrolled glaucoma in the study eye defined as intraocular pressure (IOP) > 25 mmHg on medication or according to Investigator's judgment at Screening or Baseline
  12. Aphakia and/or absence of the posterior capsule in the study eye at Screening or Baseline, unless it occurred as a result of a YAG posterior capsulotomy in association with prior posterior chamber intraocular lens implantation
  13. Intra or periocular use of in the study eye within a 6 month period prior to Baseline
  14. Use of topical ocular corticosteroids in the study eye for 30 or more consecutive days within the 90 days period prior to Baseline
  15. Previous therapeutic radiation near the region of the study eye
  16. Concomitant conditions or ocular disorders in the study eye, including media opacities, cataract and diabetic macular edema, at Screening or Baseline which could, in the opinion of the Investigator, prevent response to study treatment or may confound interpretation of study results (efficacy and safety), compromise visual acuity or require medical or surgical intervention during the course of the study
  17. Presence of amblyopia, amaurosis or ocular disorders with BCVA \<38 letters (ETDRS testing charts) in the fellow eye at Screening (except when due to conditions whose surgery may improve VA, e.g. cataract)
  18. Presence of Scleromalacia in either eye
  19. Participants requiring anti-VEGF treatment of the fellow eye at Baseline will not be eligible for the PK substudy

    Systemic conditions and treatments:

  20. Previous systemic treatment with any anti-VEGF therapy
  21. Use of systemic corticosteroids for 30 or more consecutive days within the 90 days prior to Baseline, with the exception of low stable doses of corticosteroids (defined as ≤ 10 mg prednisolone or equivalent dose used for 90 days or more).
  22. Uncontrolled blood pressure defined as a systolic value ≥ 160 mmHg or diastolic value ≥ 100 mmHg at Screening
  23. Stroke or myocardial infarction during the 6-month period prior to Baseline
  24. Participation in an investigational systemic drug, biologic, or device study within 30 days or duration of 5 half-lives of the investigational product (whichever is longer) prior to Baseline. Note: observational clinical studies solely involving over-the-counter vitamins, supplements, or diets are not exclusionary
  25. Presence of infection at screening or active infection within 2 weeks before screening
  26. Underlying advanced, severe and uncontrolled concomitant condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, inflammatory, infectious or gastrointestinal), physical examination finding, or clinical laboratory finding which in the opinion of the Investigator place the participant at unacceptable risk from participation in the study
  27. History of a medical condition (including, but not limited to chronic disease , metabolic dysfunction, prior exposure to other drugs that may pose risk of infection or allergic reactions) that, in the judgment of the Investigator, would preclude scheduled study visits, completion of the study, or a safe administration of investigational product, or that might affect participant safety or interpretation of the study results.
  28. Pregnant or nursing (lactating) women and women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of while taking study treatment and for 3 months after stopping the medication. Highly effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks before taking investigational drug. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
    • Male sterilization (at least 6 months prior to screening). For female participants on the study, the vasectomized male partner should be the sole partner for that participant.
    • Use of oral (estrogen and progesterone), injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
485 participants (actual)

Study arms

  • Experimental
    SOK583A1 (40 mg/mL)

    Intravitreal (IVT) administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.

    Biological: SOK583A1 (40 mg/mL)

  • Active comparator
    Eylea EU (40 mg/mL)

    IVT administration of 2 mg of Eylea EU in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48. EU: European

    Biological: Eylea EU (40 mg/mL)

Interventions

  • BiologicalSOK583A1 (40 mg/mL)

    Drug page: Aflibercept

    IVT administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.

  • BiologicalEylea EU (40 mg/mL)

    IVT administration of 2 mg of Eylea EU in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.

06

What researchers measure

Primary outcomes

  1. Best-Corrected Visual Acuity (BCVA) Will be Assessed Using the ETDRS Testing Charts at an Initial Distance of 4 Meters. The Change From Baseline in BCVA in Letters is Defined as Difference Between BCVA Score Between Week 8 and Baseline.

    The primary aim of the study is to demonstrate equivalence of change in BCVA score from Baseline at Week 8 between participants with nAMD treated with SOK583A1 and participants treated with Eylea EU. The primary analysis will be performed on the Per-Protocol Set (PPS), which is the most appropriate analysis set to use when testing for equivalence. ETDRS: Early Treatment Diabetic Retinopathy Study EU: European

    Time frame: Change from baseline in mean BCVA score at Week 8

Secondary outcomes

  1. Similarity in the Anatomical Outcome Between SOK583A1 and Eylea EU

    Mean change in CSFT using SD-OCT from Baseline to Week 1, 4, 8, 24 and 52 CSFT: Central Subfield Thickness SD-OCT: Spectral-Domain Optical Coherence Tomography

    Time frame: Week 1, 4, 8, 24 and 52

  2. Similarity in the Anatomical Outcome Between SOK583A1 and Eylea EU

    Mean change of CNV lesion size using FA from Screening to Week 8 and 52 CNV: Choroidal neovascularization FA: Fundus Angiography

    Time frame: Week 8 and 52

  3. Similarity of Efficacy Between SOK583A1 and Eylea EU in Terms of BCVA

    Mean change from Baseline in BCVA score using EDTRS testing charts at Week 24 and 52

    Time frame: Week 24 and 52

  4. Similarity Between SOK583A1 and Eylea EU in Terms of Safety

    Number and proportion of subjects with ocular and non-ocular Adverse Events (AEs) over 52 weeks including serious AEs, regardless of relationship to study treatment

    Time frame: 52 weeks

  5. Similarity Between SOK583A1 and Eylea EU in Terms of Immunogenicity

    Development of binding and neutralizing Anti-drug antibodies (ADAs) up to Week 52

    Time frame: Week 52

  6. Systemic Exposure to SOK583A1 and Eylea EU in Participants of the Pharmacokinetic (PK) Assessment

    Aflibercept concentration assessments at Baseline (pre-dose) and 24 hours after the first and third injections

    Time frame: Baseline (pre-dose) and 24 hours after the first injection (day 2) and third injection (day 58)

Other outcomes

  1. Analysis Systemic VEGF Concentrations in Patients Treated With Aflibercept

    Mean VEGF concentrations

    Time frame: Assessment at Week 48 (pre-dose) and Week 52

07

Results

Posted Mar 26, 2024

Participant flow

Participant flow — Overall Study
MilestoneSOK583A1 (40 mg/mL)Eylea EU (40 mg/mL)
Started245240
Safety set244240
Full analysis set243240
Per-protocol set235226
Pk analysis set2320
Immunogenicity analysis set234231
Vegf analysis set6067
Completed216215
Not completed2925

Outcome measures

PrimaryBest-Corrected Visual Acuity (BCVA) Will be Assessed Using the ETDRS Testing Charts at an Initial Distance of 4 Meters. The Change From Baseline in BCVA in Letters is Defined as Difference Between BCVA Score Between Week 8 and Baseline.

The primary aim of the study is to demonstrate equivalence of change in BCVA score from Baseline at Week 8 between participants with nAMD treated with SOK583A1 and participants treated with Eylea EU. The primary analysis will be performed on the Per-Protocol Set (PPS), which is the most appropriate analysis set to use when testing for equivalence. ETDRS: Early Treatment Diabetic Retinopathy Study EU: European

Time frame:
Change from baseline in mean BCVA score at Week 8
Reported as:
Mean · BCVA score in letters
Best-Corrected Visual Acuity (BCVA) Will be Assessed Using the ETDRS Testing Charts at an Initial Distance of 4 Meters. The Change From Baseline in BCVA in Letters is Defined as Difference Between BCVA Score Between Week 8 and Baseline.
BCVA score in lettersSOK583A1 (40 mg/mL)Eylea EU (40 mg/mL)
Best-Corrected Visual Acuity (BCVA) Will be Assessed Using the ETDRS Testing Charts at an Initial Distance of 4 Meters. The Change From Baseline in BCVA in Letters is Defined as Difference Between BCVA Score Between Week 8 and Baseline.6.5 ± 8.986.8 ± 7.46
SecondarySimilarity in the Anatomical Outcome Between SOK583A1 and Eylea EU

Mean change in CSFT using SD-OCT from Baseline to Week 1, 4, 8, 24 and 52 CSFT: Central Subfield Thickness SD-OCT: Spectral-Domain Optical Coherence Tomography

Time frame:
Week 1, 4, 8, 24 and 52
Reported as:
Mean · μm
Similarity in the Anatomical Outcome Between SOK583A1 and Eylea EU
μmSOK583A1 (40 mg/mL)Eylea EU (40 mg/mL)
Week 1-103.6 ± 89.91-99.2 ± 86.18
Week 4-152.9 ± 123.55-140.7 ± 120.25
Week 8-165.7 ± 144.35-154.2 ± 133.43
Week 24-136.4 ± 140.19-127.5 ± 137.87
Week 52-187.9 ± 150.70-172.9 ± 142.74
SecondarySimilarity in the Anatomical Outcome Between SOK583A1 and Eylea EU

Mean change of CNV lesion size using FA from Screening to Week 8 and 52 CNV: Choroidal neovascularization FA: Fundus Angiography

Time frame:
Week 8 and 52
Reported as:
Mean · mm^2
Similarity in the Anatomical Outcome Between SOK583A1 and Eylea EU
mm^2SOK583A1 (40 mg/mL)Eylea EU (40 mg/mL)
Week 8-1.7877 ± 3.97567-1.7274 ± 3.77398
Week 52-3.7845 ± 5.21911-3.5026 ± 4.96036
SecondarySimilarity of Efficacy Between SOK583A1 and Eylea EU in Terms of BCVA

Mean change from Baseline in BCVA score using EDTRS testing charts at Week 24 and 52

Time frame:
Week 24 and 52
Reported as:
Mean · score on a scale
Similarity of Efficacy Between SOK583A1 and Eylea EU in Terms of BCVA
score on a scaleSOK583A1 (40 mg/mL)Eylea EU (40 mg/mL)
Week 246.9 ± 8.937.4 ± 9.95
Week 526.4 ± 11.917.7 ± 11.62
SecondarySimilarity Between SOK583A1 and Eylea EU in Terms of Safety

Number and proportion of subjects with ocular and non-ocular Adverse Events (AEs) over 52 weeks including serious AEs, regardless of relationship to study treatment

Time frame:
52 weeks
Reported as:
Count of participants · Participants
Similarity Between SOK583A1 and Eylea EU in Terms of Safety
ParticipantsSOK583A1 (40 mg/mL)Eylea EU (40 mg/mL)
Ocular AEs in the study eye8478
Ocular AEs in the fellow eye5551
Non-ocular AEs141141
SecondarySimilarity Between SOK583A1 and Eylea EU in Terms of Immunogenicity

Development of binding and neutralizing Anti-drug antibodies (ADAs) up to Week 52

Time frame:
Week 52
Reported as:
Count of participants · Participants
Similarity Between SOK583A1 and Eylea EU in Terms of Immunogenicity
ParticipantsSOK583A1 (40 mg/mL)Eylea EU (40 mg/mL)
ADA positive26
ADA negative232225
SecondarySystemic Exposure to SOK583A1 and Eylea EU in Participants of the Pharmacokinetic (PK) Assessment

Aflibercept concentration assessments at Baseline (pre-dose) and 24 hours after the first and third injections

Time frame:
Baseline (pre-dose) and 24 hours after the first injection (day 2) and third injection (day 58)
Reported as:
Mean · ng/ml
Systemic Exposure to SOK583A1 and Eylea EU in Participants of the Pharmacokinetic (PK) Assessment
ng/mlSOK583A1 (40 mg/mL)Eylea EU (40 mg/mL)
Day 1 (Baseline)0.0 ± 0.00.0 ± 0.0
Day 232.0 ± 24.033.3 ± 24.6
Day 5831.7 ± 21.933.6 ± 25.8
Other pre-specifiedAnalysis Systemic VEGF Concentrations in Patients Treated With Aflibercept

Mean VEGF concentrations

Time frame:
Assessment at Week 48 (pre-dose) and Week 52
Reported as:
Mean · pg/mL
Analysis Systemic VEGF Concentrations in Patients Treated With Aflibercept
pg/mLSOK583A1 (40 mg/mL)Eylea EU (40 mg/mL)
Week 48 (pre-dose)86.44 ± 77.96280.09 ± 92.155
Week 5275.14 ± 20.89273.38 ± 20.169

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SOK5835/244 (2%)39/244 (16%)58/244 (23.8%)
Eylea EU1/240 (0.4%)30/240 (12.5%)63/240 (26.3%)
Most frequent serious events
Showing 10 of 75
Most frequent serious events
EventSOK583Eylea EU
Atrial fibrillationCardiac disorders4/2442/240
DeathGeneral disorders3/2440/240
BronchitisInfections and infestations0/2442/240
PneumoniaInfections and infestations0/2442/240
DyspnoeaRespiratory, thoracic and mediastinal disorders1/2442/240
Coronary artery stenosisCardiac disorders2/2440/240
Retinal haemorrhageEye disorders2/2441/240
Femur fractureInjury, poisoning and procedural complications2/2440/240
Cerebral infarctionNervous system disorders2/2440/240
AnaemiaBlood and lymphatic system disorders1/2441/240
Most frequent other events
Most frequent other events
EventSOK583Eylea EU
Neovascular age-related macular degenerationEye disorders25/24425/240
COVID-19Infections and infestations19/24423/240
HypertensionVascular disorders11/24416/240
Visual acuity reducedEye disorders11/24412/240

Baseline characteristics

Age, Continuous
Age, Continuous(years)SOK583A1 (40 mg/mL)Eylea EU (40 mg/mL)Total
Mean75.8 ± 7.8275.7 ± 7.7275.7 ± 7.76
Age, Customized
Age, Customized(Participants)SOK583A1 (40 mg/mL)Eylea EU (40 mg/mL)Total
<75 years10398201
≥75 years140142282
Sex: Female, Male
Sex: Female, Male(Participants)SOK583A1 (40 mg/mL)Eylea EU (40 mg/mL)Total
Female137136273
Male106104210
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SOK583A1 (40 mg/mL)Eylea EU (40 mg/mL)Total
Hispanic or Latino12921
Not Hispanic or Latino225225450
Unknown or Not Reported6612
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SOK583A1 (40 mg/mL)Eylea EU (40 mg/mL)Total
American Indian or Alaska Native000
Asian161228
Native Hawaiian or Other Pacific Islander000
Black or African American011
White215214429
More than one race000
Unknown or Not Reported121325
Region of Enrollment
Region of Enrollment(Participants)SOK583A1 (40 mg/mL)Eylea EU (40 mg/mL)Total
United States464288
Europe158161319
Australia101323
Israel151227
Japan141226
08

Study locations

102 sites
  • Sandoz Investigational Site
    Phoenix, Arizona 85021, United States
  • Sandoz Investigational Site
    Arcadia, California 91006, United States
  • Sandoz Investigational Site
    Campbell, California 95008, United States
  • Sandoz Investigational Site
    Encino, California 91436, United States
  • Sandoz Investigational Site
    Fullerton, California 92835, United States
  • Sandoz Investigational Site
    Glendale, California 91203, United States
  • Sandoz Investigational Site
    Huntington Beach, California 92647, United States
  • Sandoz Investigational Site
    Pasadena, California 91107, United States
  • Sandoz Investigational Site
    Poway, California 92064, United States
  • Sandoz Investigational Site
    Redlands, California 92374, United States
  • Sandoz Investigational Site
    Sacramento, California 95841, United States
  • Sandoz Investigational Site
    Fort Myers, Florida 33912-7125, United States
  • Sandoz Investigational Site
    Pinellas Park, Florida 33782, United States
  • Sandoz Investigational Site
    Plantation, Florida 33324, United States
  • Sandoz Investigational Site
    Stuart, Florida 34994, United States
  • Sandoz Investigational Site
    Marietta, Georgia 30060, United States
  • Sandoz Investigational Site
    Oak Forest, Illinois 60452, United States
  • Sandoz Investigational Site
    Hagerstown, Maryland 21740, United States
  • Sandoz Investigational Site
    Albuquerque, New Mexico 87102, United States
  • Sandoz Investigational Site
    Great Neck, New York 11021, United States
  • Sandoz Investigational Site
    Liverpool, New York 13088, United States
  • Sandoz Investigational Site
    Rochester, New York 14620, United States
  • Sandoz Investigational Site
    Eugene, Oregon 97401, United States
  • Sandoz Investigational Site
    Rapid City, South Dakota 57701, United States
  • Sandoz Investigational Site
    Abilene, Texas 79606, United States
  • Sandoz Investigational Site
    Arlington, Texas 76012, United States
  • Sandoz Investigational Site
    Willow Park, Texas 76087, United States
  • Sandoz Investigational Site
    Lynchburg, Virginia 24502, United States
  • Sandoz Investigational Site
    Albury, New South Wales 2640, Australia
  • Sandoz Investigational Site
    Liverpool, New South Wales 2170, Australia
  • Sandoz Investigational Site
    Parramatta, New South Wales 2150, Australia
  • Sandoz Investigational Site
    Sydney, New South Wales 2000, Australia
  • Sandoz Investigational Site
    Adelaide, South Australia 5000, Australia
  • Sandoz Investigational Site
    Melbourne, Victoria 3002, Australia
  • Sandoz Investigational Site
    Linz, Oberoesterreich A 4020, Austria
  • Sandoz Investigational Site
    Linz, Upper Austria 4021, Austria
  • Sandoz Investigational Site
    Graz, A-8036, Austria
  • Sandoz Investigational Site
    Sofia, 1784, Bulgaria
  • Sandoz Investigational Site
    Pardubice, 530 02, Czechia
  • Sandoz Investigational Site
    Praha 5, 150 00, Czechia
  • Sandoz Investigational Site
    Praha, 12808, Czechia
  • Sandoz Investigational Site
    Marseille, Bouches-Du-Rhone 13008, France
  • Sandoz Investigational Site
    Saint Cyr sur Loire, Indre Et Loire 37540, France
  • Sandoz Investigational Site
    Paris, 75015, France
  • Sandoz Investigational Site
    Duesseldorf, 40212, Germany
  • Sandoz Investigational Site
    Frankfurt Am Main, 60596, Germany
  • Sandoz Investigational Site
    Freiburg, 79106, Germany
  • Sandoz Investigational Site
    Hannover, 30625, Germany
  • Sandoz Investigational Site
    Leipzig, 04103, Germany
  • Sandoz Investigational Site
    Mainz, 55131, Germany
  • Sandoz Investigational Site
    Marburg, 35043, Germany
  • Sandoz Investigational Site
    Budapest, HUN 1204, Hungary
  • Sandoz Investigational Site
    Budapest, Pest Megye 1134, Hungary
  • Sandoz Investigational Site
    Budapest, H-1085, Hungary
  • Sandoz Investigational Site
    Budapest, H-1136, Hungary
  • Sandoz Investigational Site
    Debrecen, 4032, Hungary
  • Sandoz Investigational Site
    Sopron, H-9400, Hungary
  • Sandoz Investigational Site
    Szeged, H-6720, Hungary
  • Sandoz Investigational Site
    Szekesfehervar, H-8000, Hungary
  • Sandoz Investigational Site
    Haifa, 3434104, Israel
  • Sandoz Investigational Site
    Jerusalem, 9112001, Israel
  • Sandoz Investigational Site
    Kfar Saba, 44281, Israel
  • Sandoz Investigational Site
    Lod, 6093000, Israel
  • Sandoz Investigational Site
    Petach Tikva, 4941492, Israel
  • Sandoz Investigational Site
    Rehovot, 7610001, Israel
  • Sandoz Investigational Site
    Tel Aviv, 6423906, Israel
  • Sandoz Investigational Site
    Nagakute-city, Aichi 480-1195, Japan
  • Sandoz Investigational Site
    Nagoya, Aichi 457 8510, Japan
  • Sandoz Investigational Site
    Nagoya, Aichi 466 8560, Japan
  • Sandoz Investigational Site
    Fukuoka city, Fukuoka 812-8582, Japan
  • Sandoz Investigational Site
    Kure, Hiroshima 737-0029, Japan
  • Sandoz Investigational Site
    Amagasaki city, Hyogo 660 8550, Japan
  • Sandoz Investigational Site
    Kobe-shi, Hyogo 650-0017, Japan
  • Sandoz Investigational Site
    Inashiki-gun, Ibaraki 300-0395, Japan
  • Sandoz Investigational Site
    Kagoshima city, Kagoshima 890 8520, Japan
  • Sandoz Investigational Site
    Hamamatsu-city, Shizuoka 430-8558, Japan
  • Sandoz Investigational Site
    Meguro-ku, Tokyo 152-8902, Japan
  • Sandoz Investigational Site
    Taito-ku, Tokyo 111-0051, Japan
  • Sandoz Investigational Site
    Ube, Yamaguchi 755-8505, Japan
  • Sandoz Investigational Site
    Riga, 1002, Latvia
  • Sandoz Investigational Site
    Riga, LV-1007, Latvia
  • Sandoz Investigational Site
    Kaunas, Kauno Apskritis 50161, Lithuania
  • Sandoz Investigational Site
    Vilnius, LT-08661, Lithuania
  • Sandoz Investigational Site
    Krakow, Malopolska 30-394, Poland
  • Sandoz Investigational Site
    Bydgoszcz, 85-631, Poland
  • Sandoz Investigational Site
    Lodz, 91-134, Poland
  • Sandoz Investigational Site
    Lublin, 20-079, Poland
  • Sandoz Investigational Site
    Wroclaw, 53-334, Poland
  • Sandoz Investigational Site
    Coimbra, 3000-548, Portugal
  • Sandoz Investigational Site
    Coimbra, 3030-363, Portugal
  • Sandoz Investigational Site
    Porto, 4200 319, Portugal
  • Sandoz Investigational Site
    Zilina, Slovak Republic 010 01, Slovakia
  • Sandoz Investigational Site
    Bratislava, 821 01, Slovakia
  • Sandoz Investigational Site
    Bratislava, 83301, Slovakia
  • Sandoz Investigational Site
    Trencin, 91171, Slovakia
  • Sandoz Investigational Site
    Oviedo, Asturias 33012, Spain
  • Sandoz Investigational Site
    Sant Cugat, Catalunya 08190, Spain
  • Sandoz Investigational Site
    Pamplona, Navarra 31008, Spain
  • Sandoz Investigational Site
    Bilbao, Pais Vasco 48006, Spain
  • Sandoz Investigational Site
    Barcelona, 08021, Spain

Showing the first 100 of 102 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Jul 2022, 13 months.

Results were first posted in Mar 2024, 1 year 8 months after primary completion. A results delay was requested in Jun 2023.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 13 months is below that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2021
First posted
Apr 29, 2021
StartActual
May 12, 2021
Primary completionActual
Jul 7, 2022
CompletionActual
May 10, 2023
Results delay requested
Jun 13, 2023
Results first posted
Mar 26, 2024
Last update
Mar 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04864834
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Apr 29, 2021
Start date
May 12, 2021
Primary completion
Jul 7, 2022
Completion
May 10, 2023
Results posted
Mar 26, 2024
Last update
Mar 26, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion